Tianjin Pharmaceutical Da Ren Tang Group Corporation (600329.SH): Saglitin Metformin Sustained Release Tablets (I) have obtained the drug registration certificate.

Tianjin Pharmaceutical Da Ren Tang Group Corporation (600329.SH) announced that its subsidiary, Tianjin Pharmaceutical Da Ren Tang Group Corporation New Drug Factory, recently received the Drug Registration Certificate for Saxagliptin Metformin Extended-release Tablets () issued by the National Medical Products Administration. Saxagliptin Metformin Extended-release Tablets (), when combined with diet and exercise, are suitable for adult patients with type 2 diabetes who are treated with saxagliptin and metformin to improve blood glucose control in these patients (see the instructions for details). This product was jointly developed by Bristol-Myers Squibb and AstraZeneca and has broad market application prospects in the field of long-term glycemic control in type 2 diabetes and chronic disease management. According to the Meini Database, the sales of Saxagliptin Metformin Extended-release Tablets () have maintained significant growth in recent years, with an estimated total domestic sales of approximately 480 million yuan in 2025, an increase of about 33% compared to 2024.